ORLANDO, Fla., Feb. 21, 2008 (PRIME NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies Inc., today announced that it has issued a third quarter 2007 research update for Osteologix Inc. (OTCBB:OLGX).
Richa Kalia, MA, RedChip Research Analyst, wrote in the report:
"The highlight of the third quarter was the successful completion of Phase II trials for OLGX's sole and lead drug, NB S101 (strontium malonate). The 12-week Phase II STRONG Study, carried out on 289 postmenopausal women with low bone mineral density, evaluated three dose levels of NB S101 and one dose level of a similar product that is approved for treatment and prevention of osteoporosis in Europe.
"We continue to maintain a 'Speculative Buy' rating on OLGX shares with a one-year price target of $3.88. We rate these shares speculative because we acknowledge there are inherent risks and uncertainties involved in this investment. OLGX is at least six years away from generating revenues if it sells its product on its own. Our model assumes that NB S101 will capture 2% of the worldwide osteoporosis market in 2014."
To receive a complimentary copy of the RedChip Visibility Third Quarter Research Report for Osteologix Inc., please visit:
http://www.redchip.com/visibility/about.asp?page=vreport&reportid=88&from=02212008news
About RedChip Companies, Inc.
RedChip Companies is an international small-cap research and financial public relations firm with offices in Beijing and Orlando and affiliates in New York and San Diego. Dedicated to "Discovering Tomorrow's Blue Chips Today(tm)," RedChip delivers concrete, measurable results for its clients through its extensive international market expertise as well as its comprehensive platform of products and services, which include RedChip Research(tm), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences held throughout the United States, and RedChip Radio(tm). To learn more about RedChip's products and services please visit:
http://www.redchip.com/visibility/services.asp
DISCLOSURES
The analysts contributing to this report do not hold any shares of OLGX. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. RedChip certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report. Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change. RedChip Companies Inc. is an affiliate of the Aurelius Consulting Group, Inc. Osteologix, Inc. is a client of the Aurelius Consulting Group, Inc. and of RedChip Visibility, a division of RedChip Companies. OLGX paid RedChip Visibility $32,400 for the RedChip Visibility Research Program, which includes this report.